ExeVir receives EIB risk finance for multiple COVID-19 nanobody - European Biotechnology

Retrieved on: 2023-01-09 11:17:59

Tags for this article:

Click the tags to see associated articles and topics

ExeVir receives EIB risk finance for multiple COVID-19 nanobody - European Biotechnology. View article details on hiswai:

Excerpt

With the help of a €25m loan from the European Investment Bank, ExeVir BIO BV will advance clinical trials with its COVID-19 nanobody XVR012.

Article found on: european-biotechnology.com